trending Market Intelligence /marketintelligence/en/news-insights/trending/a-z_4qebrky9bvkhjznt2w2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Daiichi Sankyo licenses Glycotope's potential cancer therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Daiichi Sankyo licenses Glycotope's potential cancer therapy

Japan's Daiichi Sankyo Co. Ltd. entered into an exclusive worldwide licensing agreement with Glycotope GmbH for its potential cancer treatment gatipotuzumab.

The deal gives Daiichi worldwide exclusive rights to develop and commercialize Glycotope's investigational antibody gatipotuzumab and combine it with its antibody drug conjugate, or ADC, technology.

ADCs are targeted cancer medicines that deliver chemotherapy to cancer cells that binds to a specific target expressed on cancer cells.

Under the deal, Berlin-based Glycotope will receive an up-front payment and potential milestone payments and royalties on sales from Daiichi Sankyo.

The companies did not disclose the financial terms of the deal in a July 30 news release.